I3S - INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTO

Their core work

I3S is a biomedical research institute affiliated with the University of Porto, focused on health sciences with particular strength in pharmacology, reproductive health, and in vitro modelling. Their work spans drug safety assessment during pregnancy, bioprinting technologies, and biomechanical modelling of biological barriers like the placenta. They also engage in science-society initiatives including public engagement and researcher mobility within European university alliances.

What they specialise in

How they've shifted over time

All three H2020 projects began in 2021, so there is no long-term evolution visible within this dataset. Early keyword signals point toward broad institutional themes — global health alliances, knowledge transfer, and business-academia cooperation — while the more detailed project work (LIFESAVER) reveals deep specialization in reproductive pharmacology and advanced in vitro technologies. This suggests I3S entered H2020 through network-building activities and then secured a substantial research role in their core scientific domain.

I3S is moving from broad European networking toward focused biomedical research in reproductive health and advanced tissue modelling, making them increasingly relevant for regulatory science and pharmaceutical safety partnerships.

How they like to work

I3S has never coordinated an H2020 project — they participate as a partner or third party, contributing specialist expertise to larger consortia. With 28 unique partners across 11 countries from just 3 projects, they operate within broad, multi-national networks rather than small focused teams. This profile suggests they are a reliable contributor brought in for specific scientific capabilities rather than a consortium-building leader.

Despite only 3 projects, I3S has connected with 28 partners across 11 countries, reflecting participation in large European consortia. Their network is geographically diverse with no single dominant partner country visible from this data.

What sets them apart

I3S combines pharmacological expertise with advanced bioprinting and biomechanical modelling — a rare intersection useful for building organ-on-chip and placental barrier models for drug safety testing. As part of the University of Porto ecosystem, they bring institutional credibility and access to core research facilities. For anyone building a consortium around maternal health, pharmaceutical regulation, or biological tissue modelling, I3S offers a specific and hard-to-replace competence.

Highlights from their portfolio

• LIFESAVER
  Their largest project (EUR 512K, running to 2025) combining drug safety, placental modelling, and bioprinting — represents their core scientific identity.
• EUGLOHRIA
  Part of a European university alliance for global health and pandemic response, showing I3S's integration into high-level institutional research networks.